Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial
- 1 February 2015
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 135 (2) , 281-288
Abstract
No abstract availableKeywords
Funding Information
- Bayer Pharma AG
- Bayer HealthCare Pharmaceuticals
This publication has 30 references indexed in Scilit:
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE studyJournal of Thrombosis and Thrombolysis, 2009
- Incidence and mortality of venous thrombosis: a population‐based studyJournal of Thrombosis and Haemostasis, 2007
- Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary EmbolismNew England Journal of Medicine, 2004
- Natural History of Venous ThromboembolismCirculation, 2003
- Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 2000
- Incidence of Venous Thromboembolism: A Community-based Study in Western FranceThrombosis and Haemostasis, 2000
- Trends in the Incidence of Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 1998
- Prevalence of Acute Pulmonary Embolism Among Patients in a General Hospital and at AutopsyChest, 1995
- A Population-Based Perspective of the Hospital Incidence and Case-Fatality Rates of Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 1991